Cleerly Unveils AI-Driven Heart Disease Risk Assessment Tool

2025-03-28 digitalcare

New York, Friday, 28 March 2025.
Cleerly’s innovative AI solution accurately measures heart disease risk by identifying plaque buildup, making strides in preventive cardiology and winning the AI Breakthrough Award.

Significant Financial Backing and Growth

Cleerly’s innovative approach to cardiovascular health has attracted substantial investor confidence, securing $223 million in Series C funding in 2022, followed by an additional $106 million in Series C extension funding in December 2024 [4]. The company, founded in 2017, has established a strong presence with operations across multiple locations including Denver, New York, Dallas, and Lisbon [4], indicating robust market expansion and technological development capability.

Revolutionary Technology Implementation

The company’s breakthrough technology employs AI-driven precision diagnostic solutions that focus on comprehensive quantification of atherosclerosis [1]. In a recent demonstration of its practical application, Cleerly partnered with Corazon Imaging and Philips to provide 14 analyses and on-site CCTA scans, showcasing the technology’s potential for improving equitable access to advanced heart care [2]. The system’s effectiveness is particularly noteworthy in detecting soft plaque, a critical indicator that often goes unnoticed in traditional diagnostic procedures [5].

Clinical Validation and Future Developments

Cleerly is set to present groundbreaking clinical trial results at the American College of Cardiology Annual Scientific Session (ACC.25) from March 29-31, 2025, in Chicago. The presentation will specifically address AI-based Quantitative Computed Tomography’s role in identifying future cardiovascular event risks in women [7]. This development comes at a crucial time when AI is increasingly being integrated into cardiac imaging, with new technologies enhancing image quality and reducing radiation exposure [8].

Market Impact and Healthcare Integration

The company’s commitment to innovation is evidenced by its extensive intellectual property portfolio, protected by numerous U.S. patents [1]. This technological advancement aligns with broader industry trends, as healthcare providers increasingly recognize the value of AI-driven cardiac assessment tools. The technology’s non-invasive nature and ability to provide detailed plaque analysis represent a significant step forward in preventive cardiology [1][4], potentially transforming how heart disease is diagnosed and treated across the healthcare sector.

Bronnen

AI healthcare heart disease